Skip to main content

Multiple sclerosis is a disease in which an individual’s own immune system attacks the fatty myelin sheath which is a protective layer that covers the nerve fibres, causing communication problems between the brain and rest of the body resulting into a permanent damage or deterioration and eventually death. Data shows that nearly 15% of the the people suffering from multiple sclerosis experience a subset of the disease known as primary-progressive multiple sclerosis which is characterised by gradual onset and steady progression of signs and symptoms. Recently U.S.Food and Drug Administration (FDA) approved therapeutic monoclonal antibody with a novel target as the first and only treatment for primary-progressive multiple sclerosis patients. 

The FDA ruled on ofatumumab in August 2020. But the only FDA-approved medication for the struggling subset of multiple sclerosis with the primary-progressive condition is ocrelizumab making it the only drug for such patients for whom no treatment existed so far.


InnoHEALTH magazine digital team

Author InnoHEALTH magazine digital team

More posts by InnoHEALTH magazine digital team

Leave a Reply